354 related articles for article (PubMed ID: 31408438)
1. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.
Fajgenbaum DC; Langan RA; Japp AS; Partridge HL; Pierson SK; Singh A; Arenas DJ; Ruth JR; Nabel CS; Stone K; Okumura M; Schwarer A; Jose FF; Hamerschlak N; Wertheim GB; Jordan MB; Cohen AD; Krymskaya V; Rubenstein A; Betts MR; Kambayashi T; van Rhee F; Uldrick TS
J Clin Invest; 2019 Aug; 129(10):4451-4463. PubMed ID: 31408438
[TBL] [Abstract][Full Text] [Related]
2. Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO.
Phillips AD; Kakkis JJ; Tsao PY; Pierson SK; Fajgenbaum DC
J Cell Mol Med; 2022 Jun; 26(11):3147-3152. PubMed ID: 35488725
[TBL] [Abstract][Full Text] [Related]
3. Increased mTOR activation in idiopathic multicentric Castleman disease.
Arenas DJ; Floess K; Kobrin D; Pai RL; Srkalovic MB; Tamakloe MA; Rasheed R; Ziglar J; Khor J; Parente SAT; Pierson SK; Martinez D; Wertheim GB; Kambayashi T; Baur J; Teachey DT; Fajgenbaum DC
Blood; 2020 May; 135(19):1673-1684. PubMed ID: 32206779
[TBL] [Abstract][Full Text] [Related]
4. Targeting the mTOR pathway in idiopathic multicentric Castleman disease.
Stern RM; Berliner N
J Clin Invest; 2019 Oct; 129(10):4086-4088. PubMed ID: 31524635
[TBL] [Abstract][Full Text] [Related]
5. Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease.
Pai RL; Japp AS; Gonzalez M; Rasheed RF; Okumura M; Arenas D; Pierson SK; Powers V; Layman AAK; Kao C; Hakonarson H; van Rhee F; Betts MR; Kambayashi T; Fajgenbaum DC
JCI Insight; 2020 May; 5(9):. PubMed ID: 32376796
[TBL] [Abstract][Full Text] [Related]
6. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
Fajgenbaum DC
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327
[TBL] [Abstract][Full Text] [Related]
7. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series.
Lust H; Gong S; Remiker A; Rossoff J
Pediatr Blood Cancer; 2021 Oct; 68(10):e29261. PubMed ID: 34302703
[TBL] [Abstract][Full Text] [Related]
8. Exploring the role of insulin-like growth factor binding protein-1 in identifying idiopathic multicentric Castleman's disease types: Implications for the mTOR signaling pathway.
Sumiyoshi R; Koga T; Fukui S; Furukawa K; Momoki M; Ichinose K; Yano S; Kawakami A
Clin Immunol; 2023 Nov; 256():109798. PubMed ID: 37778714
[TBL] [Abstract][Full Text] [Related]
9. Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports.
Ferrero S; Ragaini S
J Med Case Rep; 2021 Mar; 15(1):105. PubMed ID: 33676575
[TBL] [Abstract][Full Text] [Related]
10. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
Fajgenbaum DC
Blood; 2018 Nov; 132(22):2323-2330. PubMed ID: 30487129
[TBL] [Abstract][Full Text] [Related]
11. Hepatic Campylobacter jejuni infection in patients with Castleman-Kojima disease (idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome).
Kageyama C; Igawa T; Gion Y; Iwaki N; Tabata T; Tanaka T; Kondo E; Sakai H; Tsuneyama K; Nomoto K; Noguchi H; Yoshino T; Yokota K; Sato Y
Pathol Int; 2019 Oct; 69(10):572-579. PubMed ID: 31631463
[TBL] [Abstract][Full Text] [Related]
12. The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome.
Kurose N; Futatsuya C; Mizutani KI; Kumagai M; Shioya A; Guo X; Aikawa A; Nakada S; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Kojima M; Nakamura S; Yamada S
Hum Pathol; 2018 Jul; 77():130-138. PubMed ID: 29684500
[TBL] [Abstract][Full Text] [Related]
13. Immunology and targeted therapy in Castleman disease.
Tsunoda S; Harada T; Kikushige Y; Kishimoto T; Yoshizaki K
Expert Rev Clin Immunol; 2024 May; ():1-12. PubMed ID: 38785062
[TBL] [Abstract][Full Text] [Related]
14. Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease.
Pierson SK; Stonestrom AJ; Shilling D; Ruth J; Nabel CS; Singh A; Ren Y; Stone K; Li H; van Rhee F; Fajgenbaum DC
Am J Hematol; 2018 Jul; 93(7):902-912. PubMed ID: 29675946
[TBL] [Abstract][Full Text] [Related]
15. Candidate biomarkers for idiopathic multicentric Castleman disease.
Sumiyoshi R; Koga T; Kawakami A
J Clin Exp Hematop; 2022; 62(2):85-90. PubMed ID: 35768241
[TBL] [Abstract][Full Text] [Related]
16. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.
Nishimura Y; Fajgenbaum DC; Pierson SK; Iwaki N; Nishikori A; Kawano M; Nakamura N; Izutsu K; Takeuchi K; Nishimura MF; Maeda Y; Otsuka F; Yoshizaki K; Oksenhendler E; van Rhee F; Sato Y
Am J Hematol; 2021 Oct; 96(10):1241-1252. PubMed ID: 34265103
[TBL] [Abstract][Full Text] [Related]
17. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?
Fujimoto S; Sakai T; Kawabata H; Kurose N; Yamada S; Takai K; Aoki S; Kuroda J; Ide M; Setoguchi K; Tsukamoto N; Iwao-Kawanami H; Kawanami T; Mizuta S; Fukushima T; Masaki Y
Am J Hematol; 2019 Sep; 94(9):975-983. PubMed ID: 31222819
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review.
Belyaeva E; Rubenstein A; Pierson SK; Dalldorf D; Frank D; Lim MS; Fajgenbaum DC
Hematol Oncol; 2022 Apr; 40(2):191-201. PubMed ID: 35104370
[TBL] [Abstract][Full Text] [Related]
19. Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease.
Rubenstein AI; Pierson SK; Shyamsundar S; Bustamante MS; Gonzalez MV; Milller ID; Brandstadter JD; Mumau MD; Fajgenbaum DC
Br J Haematol; 2024 Mar; 204(3):921-930. PubMed ID: 38168727
[TBL] [Abstract][Full Text] [Related]
20. TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease.
Srkalovic G; Marijanovic I; Srkalovic MB; Fajgenbaum DC
Bosn J Basic Med Sci; 2017 May; 17(2):81-84. PubMed ID: 28135567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]